Global Health Policy Blog

CGD experts blog on global health issues such as health financing, drug resistance, clinical trials, vaccine development, HIV/AIDS, and health-related foreign assistance.

 

Confronting Antimicrobial Resistance: Can We Get to Collective Action?

Imagine if a small cut could evolve into a lengthy hospital stay, or worse; if doctors refused to perform surgery or transplants due to prohibitive risk during recovery; and if our collective gains against the world’s biggest infectious killers—HIV, malaria, tuberculosis, sexually transmitted infections, pneumonia, and more—slowed, stalled, and reversed. These nightmare scenarios could become the new global reality if common pathogens evolve to withstand and survive treatment with antimicrobial drugs, a phenomenon known as antimicrobial resistance (AMR).

How Could the Global Fund Get More Health for Its Money? Lessons from the Economics of Contract Theory

Our recent report on next generation financing models looks at how global health donors, specifically the Global Fund to Fight AIDS, Tuberculosis and Malaria, can enhance the health impact of grants by tying grant payments to achieved and verified results. Yet there are several ways to condition payments on performance, and some ways would likely work better than others.  Can economic theory suggest specific features of contract designs which would generate more health for the money?  

Pages

Tags

Experts